Key result
ACE inhibitors and ARBs slow chronic renal disease progression in hypertension.
Why the study?
Hypertension contributes to the progression of chronic renal disease through multiple mechanisms, with a pronounced effect in African-Americans who have higher prevalence of hypertension and end-stage renal disease.
Do ACEIs and AT II blockers reduce the progression of chronic renal disease in patients with hypertension?
Population
Patients with hypertension and chronic renal disease, including African-Americans
Comparison
ACEIs and AT II blockers versus no treatment or other therapies
Design
Review
Authors
Loading...
May support ACEI/ARB use to slow hypertensive CKD progression; leaves open need for updated RCTs.
Do ACEIs and AT II blockers reduce the progression of chronic renal disease in patients with hypertension?
ACE inhibitors and angiotensin II receptor blockers play a major role in halting the progression of chronic renal disease associated with hypertension.
Manuel Martinez-Maldonado (2001) conducted a review in Hypertension and chronic renal disease. Hypertension was evaluated. Hypertension contributes to chronic renal disease progression, a process that can be mitigated by ACE inhibitors and angiotensin II receptor blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: